Compositions and methods for diagnosis and treatment of type 2 diabetes

A technology for type 2 diabetes and diabetes, applied in the direction of biochemical equipment and methods, drug combinations, metabolic diseases, etc., can solve the problems of rarely identifying and treating diabetes

Inactive Publication Date: 2009-10-21
AMERICAN TYPE CULTURE COLLECTION
View PDF10 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Treatment of pre-diabetes with therapeutic agents can delay or prevent diabetes; however, pre-diabetes is rarely identified and tre...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for diagnosis and treatment of type 2 diabetes
  • Compositions and methods for diagnosis and treatment of type 2 diabetes
  • Compositions and methods for diagnosis and treatment of type 2 diabetes

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0189] The preparation method of the pharmaceutical composition containing the active ingredient is well known in the art, for example, by mixing, granulating or tableting processes. The active therapeutic ingredient is usually mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient. For oral administration, the active agent is mixed with additives commonly used for this purpose (e.g., solvents, stabilizers or inert diluents), and converted into a suitable administration form (e.g., tablets, coatings as detailed above) by conventional methods. Tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily solutions, etc.).

[0190] For IV administration, glucuronic acid, L-lactic acid, acetic acid, citric acid or any pharmaceutically acceptable acid / conjugate matrix with reasonable buffer capacity and pH range acceptable for intravenous administration can be used as Buffer. It is also possible to use a sodium chloride solution whose...

Embodiment 1

[0194] Example 1: Identification of biomarkers in the Cohen rat model of type 2 diabetes

[0195] Cohen Diabetes (CD) rat is a well-known universal type 2 diabetes animal model, which is composed of two rodent strains that show many common features with human type 2 diabetes (T2D). When maintaining a high sucrose / low copper diet (HSD), sensitive strains (CDs) developed diabetes within 30 days, while resistant strains (CDr) maintained normal blood glucose levels. When the regular rodent diet (RD) is maintained for a long time, neither of these two strains will develop T2D symptoms.

[0196] Sample Preparation

[0197] Serum, urine and tissue samples (including spleen tissue, pancreatic tissue and liver tissue) were collected from CDr rats and CDs rats fed RD or HSD for 30 days. The samples were snap frozen and stored at -80°C.

[0198]A whole protein extract was prepared for each of the 4 experimental conditions, and 10 organs were used in each group. A mechanical shearing device...

Embodiment 2

[0230] Example 2: Identification of biomarkers in human serum

[0231] With D3 hyperimmune serum (rabbit; Picture 11 ) The human serum was analyzed. The first antibody used is a rabbit polyclonal antibody produced after immunization with D3 peptide. Compared with patients with type 2 diabetes, the expression intensity of proteins with a molecular weight of 20kD (between 14kD and 28kD markers) in the serum of normal individuals (human) is higher. In both (normal and diabetic) samples, a pair of proteins with a molecular weight of 60-80 kD appeared to be present. Interestingly, the protein intensities in the two seem to be transformable; observations were made with monoclonal antibodies from CDr-HSD pancreas and CDs-HSD pancreas from subtractive immunoassay. Figure 12A with Figure 12B Represents a preparative gel containing 100 μg CDr-HSD or CDs-HSD pancreatic extract. The positive control was stained with 20 μg of anti-actin antibody, and the subcloning lane was stained with 6...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

he present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

Description

Invention field [0001] The present invention generally relates to methods for identifying biomarkers related to the increased risk of developing diabetes, and methods for using these biomarkers in the diagnosis and prognosis of diabetes. In addition, the biomarkers selected in the present invention provide new therapeutic targets for the treatment or prevention of diabetes and constitute new therapeutic drugs. Background of the invention [0002] Diabetes includes a group of diseases characterized by chronic hyperglycemia. It is caused by the body's inability to produce and / or use insulin (a hormone that is produced by pancreatic beta cells and plays an important role in metabolism). Symptoms include thirst and polyuria, hunger, weight loss, chronic infection, slow wound healing, fatigue, and blurred vision. However, the symptoms are usually not serious, unrecognized or asymptomatic. Diabetes can cause debilitating and fatal complications, including blinding retinopathy, memory l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N24/00G01N33/00G01N33/53G01N33/543G01N33/551G01N21/00
CPCC12Q2600/158C12Q1/6883A61P3/10
Inventor C·盖尔伯L·刘
Owner AMERICAN TYPE CULTURE COLLECTION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap